Chest
The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Section snippets
1.0 Pharmacology and Monitoring of VKAs
The VKAs produce their anticoagulant effect by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide), thereby modulating the γ-carboxylation of glutamate residues (Gla) on the N-terminal regions of vitamin K-dependent proteins (Fig 1).123456 The vitamin K coagulation factors II, VII, IX, and X require γ-carboxylation for their procoagulant activity, and treatment with coumarins results in the hepatic production of partially carboxylated and
1.1 Pharmacokinetics and pharmacodynamics of warfarin
Warfarin is the most common coumarin that is in clinical use. It is a racemic mixture of two optically active isomers, the R and S forms. Warfarin is rapidly absorbed from the GI tract, has high bioavailability,1819 and reaches maximal blood concentrations about 90 min after oral administration.1820 Warfarin has a half-life of 36 to 42 h,21 circulates bound to plasma proteins (mainly albumin), and accumulates in the liver, where the two isomers are metabolically transformed by different
1.2 The antithrombotic effect of VKAs
The antithrombotic effect of VKAs has conventionally been attributed to their anticoagulant effect, which in turn is mediated by the reduction of four vitamin K-dependent coagulation factors. More recent evidence, however, suggests that the anticoagulant and antithrombotic effects can be dissociated, and that the reduction of prothrombin and possibly factor X are more important than the reduction of factors VII and IX for the antithrombotic effect. This evidence is indirect and has been derived
1.3 Monitoring anticoagulation intensity
The PT test75 is the most common test used to monitor VKA therapy. The PT responds to a reduction of three of the four vitamin K-dependent procoagulant clotting factors (ie, II, VII, and X) that are reduced by warfarin at a rate proportional to their respective half-lives. Thus, during the first few days of warfarin therapy the PT reflects mainly a reduction of factor VII, the half-life of which is approximately 6 h. Subsequently, the reduction of factors X and II contributes to prolongation of
1.4 Clinical applications of VKA therapy
The clinical effectiveness of VKAs in the treatment of a variety of disease conditions has been established by well-designed clinical trials. VKAs are effective for the primary and secondary prevention of venous thromboembolism, for the prevention of systemic embolism in patients with prosthetic heart valves or atrial fibrillation, for the prevention of acute myocardial infarction in patients with peripheral arterial disease and in men who otherwise are at high risk, and for the prevention of
2.0 Management of VKA Therapy
Utilizing the correct intensity of a coumarin anticoagulant and maintaining the patient in the therapeutic range are two of the most important determinants of its therapeutic effectiveness and safety. High-quality dose management is essential to achieve and maintain therapeutic efficacy. Attainment of this goal can be influenced by physiologic and pharmacologic factors such as interacting drugs or illnesses that affect the pharmacokinetics or pharmacodynamics of warfarin, dietary or GI factors
2.1.1 Initiation and maintenance dosing
Following the administration of warfarin, an initial effect on the PT usually occurs within the first 2 or 3 days, depending on the dose administered, and an antithrombotic effect occurs within the next several days.138139 Heparin should be administered concurrently when a rapid anticoagulant effect is required, and its administration should be overlapped with warfarin until the INR has been in the therapeutic range for at least 2 days. A loading dose (ie, > 20 mg) of warfarin is not
Recommendations
2.1.1.1. We suggest the initiation of oral anticoagulation with doses between 5 and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the INR response (Grade 2B).
Recommendations
2.1.3.1. We suggest that INR monitoring should be started after the initial two or three doses of oral anticoagulation therapy (Grade 2C).
2.1.3.2. For patients who are receiving a stable dose of oral anticoagulants, we suggest monitoring at an interval of no longer than every 4 weeks (Grade 2C).
Recommendations
2.1.4.1. For patients with INRs above the therapeutic range, but < 5.0 and with no significant bleeding, lower the dose or omit the dose, monitor more frequently, and resume therapy at a lower dose when the INR is at a therapeutic level. If only minimally above therapeutic range, no dose reduction may be required (all Grade 2C).
2.1.4.2. For patients with INRs of ≥ 5.0 but < 9.0 and no significant bleeding, omit the next one or two doses, monitor more frequently, and resume therapy at lower dose
Recommendations
2.1.5.1 For patients with a low risk of thromboembolism, stop warfarin therapy approximately 4 days before they undergo surgery, allow the INR to return to near-normal values, briefly use postoperative prophylaxis (if the intervention increases the risk of thrombosis) with low-dose UFH (5,000 U SC) or a prophylactic dose of LMWH, and simultaneously begin warfarin therapy. Alternatively, a low dose of UFH or a prophylactic dose of LMWH also can be used preoperatively (all Grade 2C).
2.1.5.2. For
Recommendation
2.1.6.1. In patients who have a lupus inhibitor who have no additional risk factors and no lack of response to therapy, we suggest a therapeutic target INR of 2.5 (INR range, 2.0 to 3.0) [Grade 2B]. In patients who have recurrent thromboembolic events with a therapeutic INR or other additional risk factors for thromboembolic events, we suggest a target INR of 3.0 (INR range, 2.5 to 3.5) [Grade 2C].
2.1.1 The Appropriate Dose for Initiation of Oral Anticoagulants
2.1.1.1. We suggest the initiation of oral anticoagulation therapy with doses between 5 and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the INR response (Grade 2B).
2.1.2 Anticoagulation in the Elderly
2.1.2.1. In the elderly, for patients who are debilitated, malnourished, have congestive heart failure, or have liver disease we suggest the use of a starting dose of ≤ 5 mg (Grade 2C).
2.1.3 Frequency of Monitoring Oral Anticoagulation Therapy
2.1.3.1. We suggest starting INR monitoring after the initial two or three doses of oral anticoagulation
References (329)
- et al.
Evidence that warfarin anticoagulant action involves two distinct reductase activities
J Biol Chem
(1982) - et al.
Normal and warfarin-resistant rat hepatocyte metabolism of vitamin K 2,3 epoxide: evidence for multiple pathways of hydroxyvitamin K formation
Arch Biochem Biophys
(1988) - et al.
The mode of action of vitamin K: identification of γ-carboxyglutamic acid as a component of prothrombin
J Biol Chem
(1974) - et al.
A spectrum of partially carboxylated prothrombins in the plasmas of coumarin treated patients
Biochim Biophys Acta
(1977) - et al.
The kinetics of activation of normal and gamma carboxy glutamic acid deficient prothrombins
J Biol Chem
(1985) Role of gamma-carboxyglutamic acid: an unusual transition required for calcium-dependent binding of prothrombin to phospholipid
J Biol Chem
(1976)- et al.
Differentiation of metal ion-induced transitions of prothrombin fragment 1
J Biol Chem
(1977) - et al.
Prothrombin requires two sequential metal-dependent conformational transitions to bind phospholipid
J Biol Chem
(1986) - et al.
Sequence of the precursor to rat bone Y-carboxyglutamic acid protein that accumulated in warfarin-treated osteosarcoma cells
J Biol Chem
(1985) - et al.
Maternal and fetal sequelae of anticoagulation during pregnancy
Am J Med
(1980)
Genetic control of anticoagulation
Lancet
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
Lancet
Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole
Am J Cardiol
Vitamin K deficiency from dietary vitamin K restriction in humans
Am J Clin Nutr
Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring anticoagulant therapy
Blood
Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range
Chest
Reliability of the international normalized ratio for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio
J Lab Clin Med
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves
Chest
Bleeding in outpatients treated with warfarin: Relation to the prothrombin time and important remediable lesions
Am J Med
Mechanisms of coumarin action: significance of vitamin K epoxide reductase inhibition
Biochemistry
The relationship between inhibition of vitamin K 1,2,3-epoxide reductase and reduction of clotting factor activity with warfarin
Br J Clin Pharmacol
Vitamin K dependent modifications of glutamic acid residues in prothrombin
Proc Natl Acad Sci U S A
Osteocalcin and matrix Gla protein: vitamin K dependent proteins in bone
Phys Rev
Role of vitamin K-dependent proteins in bone metabolism
Annu Rev Nutr
Protein S, a vitamin K-dependent protein is a bone matrix component synthesized and secreted by osteoblasts
Endocrinology
Congenital malformations associated with the administration of oral anticoagulants during pregnancy
J Pediatr
Oral anticoagulant drugs: pharmacokinetic aspects
Semin Hematol
Vitamin K and other oral anticoagulant drugs
Annu Rev Med
Clinical pharmacokinetics of oral anticoagulants
Clin Pharmacokinet
Warfarin metabolism and drug-drug interactions
Pharmacogenetics of warfarin elimination and its clinical implications
Clin Pharmacokinet
Pharmacology of warfarin and related anticoagulants
Individual variability in sensitivity to warfarin: nature or nurture
Clin Pharmacol Ther
Influence of CYP2C9 genetic variants on the risk of overanticoagulation and of bleeding events during warfarin therapy
JAMA
Hereditary resistance to coumarin anticoagulant drugs in man and rat
Ann NY Acad Sci
Hereditary transmission of exceptional resistance to coumarin anticoagulant drugs
N Engl J Med
Hereditary warfarin resistance
Arch Intern Med
Missence mutations at ALA-10 in the factor IX peopeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticaogulant therapy
Br J Haematol
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man
Clin Pharmacol Ther
Studies on the optical enantiomorphs of warfarin in man
Clin Pharmacol Ther
Stereoselective interaction of phenylbutazone with 13C/12C labelled racemates of warfarin in man [abstract]
Fed Proc
The warfarin-sulfinpyrazone interaction: stereochemical considerations
Clin Pharmacol Ther
The stereoselective interaction of warfarin and metronidazole in man
N Engl J Med
Stereoselective interaction of trimethoprim-sulamethazole with the separated enantiomorphs of racemic warfarin in man
N Engl J Med
Warfarin: stereochemical aspects of its metabolism and the interaction with phenylbutazone
J Clin Invest
Interaction of amiodorone with racemic warfarin and its separated enantimorphs in humans
Clin Pharmacol Ther
Lack of effect of fortified wine ingested during fasting and anticoagulant therapy
Arch Intern Med
A review of enzyme induction of warfarin metabolism with recommendations for patient management
Pharmacotherapy
Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methyl-thiotetrazole cephalosporins
Thromb Haemost
Prolonged bleeding times and bleeding diathesis associated with moxalactam administration
JAMA
Cited by (1104)
Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device
2022, Journal of the Formosan Medical AssociationComparison of capillary and venous blood sampling for routine coagulation assays
2022, Clinical BiochemistryDirect Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children
2022, Journal of PediatricsEighty years of oral anticoagulation: Learning from history
2021, Vascular PharmacologyAnticoagulation control among patients on vitamin K antagonists in nine countries in Sub-Saharan Africa
2024, Journal of Thrombosis and Thrombolysis